Hand-out
Press Releases
Affinia Therapeutics Announces Development Candidate for BAG3 DCM and Completion of Pre-IND Meeting with the FDA
BAG3 DCM is a devastating monogenic heart disease affecting more than 70,000 patients in the U.S., Europe, and U.K., with almost 25% of patients requiring a heart transplant
